drugset / Trial / NCT00066794

S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

NCT00066794

Non-randomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as cyclosporine, daunorubicin, and cytarabine, use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving cyclosporine together with daunorubicin and cytarabine works in treating older patients with untreated acute myeloid leukemia.

Timeline

Start
2004-07
Primary completion
2007-02
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide 16 unknown Intravenous
Subject Cytarabine Small molecule 200 mg/m2 Intravenous
Subject Daunorubicin Small molecule 45 mg/m2 Intravenous
Background filgrastim Protein / enzyme biologic 5 ug/kg Intravenous
Background sargramostim Protein / enzyme biologic 250 ug/kg Intravenous

Indications